United Therapeutics (FRA:UTH) 1-Year Share Buyback Ratio : 4.70% (As of Dec. 2024 )

View and export this data going back to . Start your Free Trial

What is United Therapeutics 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. United Therapeutics's current 1-Year Share Buyback Ratio was 4.70%.

FRA:UTH's 1-Year Share Buyback Ratio is ranked better than
97.95% of 537 companies
in the Drug Manufacturers industry
Industry Median: -1.9 vs FRA:UTH: 4.70

Competitive Comparison of United Therapeutics's 1-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

United Therapeutics 1-Year Share Buyback Ratio Calculation

United Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2023 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Dec. 2023 )
	=	(47.041	-	44.831)	/	47.041
	=	4.7%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics (FRA:UTH) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

United Therapeutics 1-Year Share Buyback Ratio Related Terms

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (FRA:UTH) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

UTHR:USA U2TH34:Brazil

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines